{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:12:33Z","timestamp":1787166753371,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Peking Union Medical College Hospital Talent Cultivation Program","award":["UBJ10800"],"award-info":[{"award-number":["UBJ10800"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-C&T-B-045"],"award-info":[{"award-number":["2023-I2M-C&T-B-045"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2025-PUMCH-A-184"],"award-info":[{"award-number":["2025-PUMCH-A-184"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic disorder characterized by a systemic cytokine storm. Interleukin-6 (IL-6) is central to iMCD pathogenesis and IL-6-targeted therapy is the preferred first-line treatment, yet most patients still receive non-anti-IL-6 regimens. We conducted a single-center retrospective study of patients with iMCD to evaluate the clinical utility of serum IL-6 monitoring\u2014at baseline and longitudinally\u2014with particular emphasis on those receiving non-anti-IL-6 therapy. Among 149 patients (660 IL-6 measurements; 76 male\/73 female; median age 45 years), 34 received anti-IL-6 therapy and 115 received non-anti-IL-6 therapy. Baseline IL-6 differed across clinical and pathologic subtypes and correlated negatively with hemoglobin and albumin, and positively with platelet count, C-reactive protein (CRP), and immunoglobulin G (IgG). Baseline IL-6 did not predict biochemical response. IL-6 dynamics were uninformative in the anti-IL-6 group; however, in the non-anti-IL-6 group, IL-6 declined significantly after treatment, with greater decreases in responders than in non-responders. Among initial responders, a directional trend toward rising IL-6 levels was observed prior to biochemical PD identification, whereas persistently suppressed IL-6 was observed in sustained remission. Early IL-6 change predicted subsequent biochemical response; at 1 month, a \u0394logIL-6 threshold of \u2212\u20090.16 achieved 91.7% sensitivity and 92.3% specificity. These findings support serum IL-6 monitoring as a useful tool for response assessment and early prediction in iMCD, especially among patients receiving non-anti-IL-6 therapies.<\/jats:p>","DOI":"10.1186\/s40364-026-00943-x","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:47:10Z","timestamp":1780314430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Serum interleukin-6 (Il-6) monitoring in idiopathic multicentric Castleman disease: important value in patients receiving non-anti-Il-6 therapy"],"prefix":"10.1186","volume":"14","author":[{"given":"Zi-han","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-han","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao-yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-an","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"12","key":"943_CR1","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","volume":"129","author":"DC Fajgenbaum","year":"2017","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8\u2013negative\/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646\u201357. https:\/\/doi.org\/10.1182\/blood-2016-10-746933.","journal-title":"Blood"},{"key":"943_CR2","doi-asserted-by":"publisher","unstructured":"Gao Y, Liu Y, Ting, Zhang M, Li SY, David C. Fajgenbaum, Zhang L, et al. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: a distinct subtype of iMCD-not otherwise specified with different clinical features and better survival. Br J Haematol. 2024;204(5):1830-1837. https:\/\/doi.org\/10.1111\/bjh.19334 PubMed PMID: 38356434; PubMed Central PMCID: PMC11090736.","DOI":"10.1111\/bjh.19334"},{"issue":"10","key":"943_CR3","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959\u201364. https:\/\/doi.org\/10.1182\/blood-2008-05-155846. PubMed PMID: 18784373.","journal-title":"Blood"},{"issue":"20","key":"943_CR4","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","volume":"132","author":"F van Rhee","year":"2018","unstructured":"van Rhee F, Voorhees P, Dispenzieri A, Foss\u00e5 A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115\u201324. https:\/\/doi.org\/10.1182\/blood-2018-07-862334. PubMed PMID: 30181172; PubMed Central PMCID: PMC6238190.","journal-title":"Blood"},{"issue":"1","key":"943_CR5","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1002\/ajh.27132","volume":"99","author":"NA Mango","year":"2024","unstructured":"Mango NA, Pierson SK, Bustamante MS, Brandstadter JD, van Rhee F, Fajgenbaum DC. Siltuximab administration results in spurious IL-6 elevation in peripheral blood. Am J Hematol. 2024;99(1):E15\u20138. https:\/\/doi.org\/10.1002\/ajh.27132. PubMed PMID: 37867418; PubMed Central PMCID: PMC10998478.","journal-title":"Am J Hematol"},{"key":"943_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-024-01588-9","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yin X, Ding S, Ge J, Ma L, Yang M, et al. Continuous therapy in HHV-8 negative Multicentric Castleman Disease and prolonged progression-free survival. J Hematol Oncol. 2024;17:60. https:\/\/doi.org\/10.1186\/s13045-024-01588-9. PubMed PMID: 39107807; PubMed Central PMCID: PMC11304649.","journal-title":"J Hematol Oncol"},{"issue":"Supplement 1","key":"943_CR7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1182\/blood-2024-201745","volume":"144","author":"A Noy","year":"2024","unstructured":"Noy A, Ohgami R, Munshi NC, Siddiqi I, Dacus KC, Watson Saltis A, et al. Burden of Idiopathic Multicentric Castleman Disease (iMCD) in the US: A Population-Level Real World Analysis Using a Health-Claims Dataset. Blood. 2024;144(Supplement 1):797. https:\/\/doi.org\/10.1182\/blood-2024-201745.","journal-title":"Blood"},{"issue":"2","key":"943_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/bloodadvances.2021004441","volume":"6","author":"S Mukherjee","year":"2022","unstructured":"Mukherjee S, Martin R, Sande B, Paige JS, Fajgenbaum DC. Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6\u2013directed therapy. Blood Adv. 2022;6(2):359\u201367. https:\/\/doi.org\/10.1182\/bloodadvances.2021004441. PubMed PMID: 34535010; PubMed Central PMCID: PMC8791564.","journal-title":"Blood Adv"},{"issue":"19","key":"943_CR9","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1158\/1078-0432.CCR-15-0134","volume":"21","author":"C Casper","year":"2015","unstructured":"Casper C, Chaturvedi S, Munshi N, Wong R, Qi M, Schaffer M, et al. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. Clin Cancer Res. 2015;21(19):4294\u2013304. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0134.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"943_CR10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/bjh.19279","volume":"204","author":"AI Rubenstein","year":"2024","unstructured":"Rubenstein AI, Pierson SK, Shyamsundar S, Sarmiento Bustamante M, Gonzalez MV, Milller ID, et al. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease. Br J Haematol. 2024;204(3):921\u201330. https:\/\/doi.org\/10.1111\/bjh.19279. PubMed PMID: 38168727; PubMed Central PMCID: PMC10998476.","journal-title":"Br J Haematol"},{"issue":"2","key":"943_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/bjh.15588","volume":"184","author":"DE Morra","year":"2019","unstructured":"Morra DE, Pierson SK, Shilling D, Nemat S, Appiani C, Guilfoyle M, et al. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. Br J Haematol. 2019;184(2):232\u201341. https:\/\/doi.org\/10.1111\/bjh.15588. PubMed PMID: 30203839; PubMed Central PMCID: PMC9547643.","journal-title":"Br J Haematol"},{"issue":"16","key":"943_CR12","doi-asserted-by":"publisher","first-page":"4773","DOI":"10.1182\/bloodadvances.2022007112","volume":"6","author":"F van Rhee","year":"2022","unstructured":"van Rhee F, Rosenthal A, Kanhai K, Martin R, Nishimura K, Hoering A, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773\u201381. https:\/\/doi.org\/10.1182\/bloodadvances.2022007112. PubMed PMID: 35793409; PubMed Central PMCID: PMC9631655.","journal-title":"Blood Adv"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00943-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-00943-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-00943-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:47:11Z","timestamp":1780314431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-00943-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["943"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-00943-x","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Peking Union Medical College Hospital (approval number: I-23PJ1862).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}